Innovative Inhaled Antipsychotic Formulation Adasuve Provides Quick and Effective Treatment

Article

Experts attending the European Psychiatry Association Congress in Vienna say that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or bipolar I disorder.

Adasuve, an oral inhalation product that combines the patented Staccato system with the antipsychotic loxapine, was approved by EMA in February 2013. The formulation has since benefitted 5000 patients in Europe, according to Rudolf Widmann, CEO of AOP Orphan, speaking at the European Psychiatry Association Congress in Vienna. Experts at the event also confirmed that Adasuve has made an impact in the treatment of agitation in patients suffering from schizophrenia or biopolar I disorder. 

In the Staccato system, loxapine is evaporated to produce an aerosol that is absorbed by the lungs. The drug is transported into the systemic circulation through the lungs, and patients notice a decrease in agitation within 10 minutes.

Available in doses of 9.1 mg, Adasuve is indicated to control cases of mild or moderate agitation in patients suffering from schizophrenia or bipolar I disorder. Patients prefer this non-invasive treatment option to an injection.

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.